{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "STAA",
  "name": "STAAR Surgical Company",
  "url": "https://orbyd.app/dossiers/STAA/",
  "json_url": "https://orbyd.app/dossiers/STAA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "China EVO+ recovery leg is decelerating: Q2 prelim (2026-07-16) of \">$90M\" was in-line, sequentially below Q1's $93.52M, and drew an 8.8% gap-down that broke the $29.43 50-day. Triple-digit YoY comps end here, the M&A binary died at the June 18 standstill expiry, and leadership is still interim. Aug 12 print is the next binary.",
  "invalidation_trigger": "A weekly close below $23.50 loses the rising 200-day and confirms the July 17 gap as a trend break rather than a flush; secondary break is the 2026-08-12 Q2 report showing China net sales flat-to-down sequentially or EMEA weakness spreading beyond the Middle East.",
  "catalyst_date": "2026-08-12",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "m-and-a-special-situations",
    "semi-foundry-equipment"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Ownership: Broadwood ~31% (Bradsher + LeBuhn on board), Yunqi Capital 6.5% (Wang on board), via 2026-01-15 cooperation agreement. Institutions 96.7%. Effective float is small — moves exaggerate in both directions.",
    "Leadership INTERIM since 2026-02-01: co-CEOs Warren Foust (Pres/COO) + Deborah Andrews (CFO), $375k RSU each. Permanent-CEO search open ~6 months. Chair Yeu and ex-CEO Farrell left the board Jan 2026. A credible external hire is the biggest single re-rate catalyst.",
    "Technical state as of 2026-07-17: price $26.44, 50-DMA $29.43 (BROKEN, now resistance), 200-DMA $23.80 (rising), 52wk range $15.59-$35.87, beta 1.23, mkt cap ~$1.3B, 49.79M shares.",
    "Fundamentals: TTM revenue $290.38M (+4.0%), TTM net income -$21.03M, EPS -$0.42, forward P/E 34.26. Quick ratio 4.31, current ratio 5.12, D/E 0.09.",
    "Analyst dispersion: consensus $27.81 (3 Buy / 6 Hold / 2 Sell panel) or $29.67 (11-analyst Buy tally) — both at/near spot. Wedbush $40 reiterated 2026-07-16 (Michael Piccolo, upgraded 2026-05-29 from Neutral, PT $26->$40), Canaccord $32, Wells Fargo $25. Broadwood's own case ~$50. Upside above ~$32 is activist/M&A-contingent, not organic.",
    "China concentration: Q1 2026 China distributors = 51% of net sales ($47.4M of $93.52M) but 57% of trade receivables. Watch collectability and sell-in pull-forward — the 2025 destocking took the stock to $15.59.",
    "Constructive re-entry conditions: higher low above the 200-day PLUS a reclaim of the $29.43 50-day on expanding volume. Do not buy the gap on the strength of the Wedbush $40 target — that target predates the sequential deceleration.",
    "Next 13F deadline 2026-08-14 reveals Broadwood/Yunqi June-quarter positioning — cleanest read on whether the anchor holder is still accumulating."
  ],
  "body_markdown": "## Current Thesis\nSTAAR Surgical sells the EVO/EVO+ ICL, an implantable collamer lens marketed as a permanent alternative to LASIK, with revenue concentrated in China. The frame has now rotated twice: first out of a merger-arbitrage special situation, and as of this week out of the clean China-recovery momentum leg that replaced it. On July 16 (after the close) the company pre-announced Q2 net sales \"in excess of $90 million\" against $44.3M in Q2 2025 — a +103% YoY figure that landed roughly on the $90.2M consensus and above Canaccord's $88.4M model. The market sold it: shares gapped from a $28.98 close to a $26.75 open on July 17 and finished $26.44, down 8.76%, cutting through the $29.43 50-day. The reason the tape disagreed with the headline is sequential. Q1 2026 printed $93.52M; Q2 came in below that, with EMEA down a low-single-digit percentage on Middle East conflict disruption offsetting sequential China growth, double-digit Americas gains, and double-digit EMEA growth excluding the Middle East. The comp math also turns here — Q2 2025's $44.3M was the destocking trough, so the triple-digit YoY headlines end with this quarter. What remains is a mid-cap ophthalmic device business at roughly $1.3B market cap, $290M TTM revenue, still loss-making on a TTM basis (-$21.03M, EPS -$0.42), trading at a 34x forward multiple with a broken 50-day and a consensus target ($27.81 from the eleven-analyst Hold-skewed panel; $29.67 on the broader Buy tally) sitting at or under spot. That combination does not support a fresh momentum entry.\n\n## Bull Case\n- **Q2 2026 preliminary net sales exceeded $90M vs $44.3M a year prior (announced 2026-07-16)** — over 103% YoY, in line with the $90.2M consensus and ahead of Canaccord's $88.4M estimate.\n- **China grew sequentially in Q2 on normalized distributor operations.** This is the second consecutive quarter of clean channel behaviour after the 2025 destocking that took shares to a $15.59 low. Q1 China contributed $47.4M of $93.5M total.\n- **Q1 2026 (2026-05-13) was a genuine beat**: net sales $93.52M (+119.6% YoY), non-GAAP EPS $0.29 against $0.08 consensus, GAAP $0.10 against roughly $0.05, with net income swinging to +$5.2M from -$54.2M.\n- **The weakness is geographic and identifiable, not demand-side.** EMEA excluding the Middle East grew double digits; the Americas grew double digits. The drag is one region under active conflict disruption.\n- **Wedbush reiterated Outperform with a $40 target on 2026-07-16**, holding the thesis it upgraded to on 2026-05-29 (from Neutral, PT lifted from $26) that STAAR is at or near a full China rebound inflection.\n- **Balance sheet gives the recovery runway**: quick ratio 4.31, current ratio 5.12, debt-to-equity 0.09.\n- **A ~31% holder with three board seats.** Broadwood Partners killed Alcon's $30.75/share ($1.6B) bid at the January 6 2026 special meeting arguing a standalone path worth materially more, then took board representation via the January 15 cooperation agreement alongside Yunqi Capital (6.5%). That block is not a seller here.\n\n## Bear Case\n- **An in-line pre-announcement drew an 8.8% selloff.** Companies pre-announce to control a narrative; the market's response to a headline that met consensus indicates positioning was leaning on a sequential acceleration that did not arrive. Q1 $93.5M into Q2 \">$90M\" is a sequential step down.\n- **The easy comparisons expire now.** Q2 2025's $44.3M was the destocking trough. From Q3 2026 the base normalizes, and triple-digit YoY growth headlines stop doing the narrative work.\n- **Price structure has broken.** The 50-day at $29.43 is now overhead resistance rather than support; the 200-day sits at $23.80. The stock is 26% off its $35.87 52-week high with no reclaim attempt yet.\n- **The M&A binary is spent.** The June 18 2026 annual meeting — the same date Broadwood's standstill on demanding a special meeting expired — produced director re-elections, a 3.9M-share equity plan increase, auditor ratification and a passing say-on-pay vote, with no sale process, strategic review, or special-meeting demand on the record. A month later there is still nothing.\n- **Leadership has been interim for six months.** Warren Foust (President/COO) and Deborah Andrews (CFO) have run the company as co-CEOs since February 1 2026, each on a $375,000 RSU grant, while a permanent-CEO search stays open. Chair Yeu and ex-CEO Farrell left the board in January.\n- **Analyst dispersion is a warning, not an opportunity.** The panel splits 3 Buy / 6 Hold / 2 Sell, with Wells Fargo at $25, Canaccord at $32 and Wedbush at $40. Consensus $27.81 is a few percent above spot; the $40 case requires the China ramp to re-accelerate, and the $25 case is already nearly satisfied.\n- **China remains over half the revenue base** with Q1 trade receivables running a higher share (57%) than sales (51%). Collectability and sell-in timing stay live risks that a single soft quarter would expose.\n- **Still unprofitable on a trailing basis** — -$21.03M net income, -$0.42 EPS — against a 34x forward multiple.\n\n## Setup & Price Structure\nShares closed $26.44 on 2026-07-17 after a gap-down from $28.98, breaking the $28–32 post-Q1 consolidation and losing the $29.43 50-day in a single session. The 200-day at $23.80 is the next structural reference, roughly 10% lower, and it is still rising — the range between here and there is where the tape decides whether this is a shakeout inside an uptrend or the start of a rollover. Beta is 1.23; institutional ownership is 96.7%, so float mechanics amplify repositioning around news like this. A momentum framework has nothing to buy in a name that just lost its 50-day on a fundamental release; the constructive version requires a higher low above the 200-day and a reclaim of $29.43 on volume. Averaging into the gap because Wedbush carries a $40 target is exactly the wrong instinct here — the target predates the sequential deceleration.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-12** — Q2 2026 full results and conference call (company-stated date; note some data vendors carry 2026-08-05, treat the company release as authoritative). The revenue line is already known; the variables are gross margin against the ~75% framing, the 2026 spend plan near $225M, China trade receivables versus sell-in, and any full-year commentary.\n- **2026-08-14** — Q2 2026 13F deadline. Broadwood's and Yunqi's June-quarter positioning becomes visible; continued accumulation versus a pause is the cleanest read on whether the standalone case still has its anchor holder behind it.\n- **Undated, live** — permanent CEO announcement. The search has been open since February 2026; a credible external hire is the single event most likely to re-rate the standalone narrative.\n- **Undated, ongoing** — Middle East conflict headlines. Management explicitly warned that intensifying geopolitical and macroeconomic pressure could weigh on future revenue growth, making EMEA a recurring quarterly swing factor.\n\n## What Would Change Our Mind\nThe constructive case turns back on if the August 12 print shows China accelerating sequentially with gross margin at or above 75% and trade receivables falling back toward the sales share, and price reclaims the $29.43 50-day on expanding volume — that would reframe the July 17 gap as a liquidation flush rather than a trend break. A permanent CEO with refractive-surgery commercial credentials, or a fresh Broadwood open-market tranche disclosed via Form 4 into this weakness, would each add weight. Conversely, a Q2 report showing China net sales flat-to-down sequentially, or EMEA weakness spreading beyond the Middle East, confirms that the recovery leg has already been priced and paid out.\n\n## Correlation Notes\nSTAA trades as a China-elective-procedure proxy wearing a medtech label. Its correlation is less with the US medtech complex than with Chinese discretionary consumption and premium elective-surgery volumes — the same demand pool that drove the 2025 destocking collapse. Peer read-throughs come from Alcon (the failed acquirer and the dominant refractive/cataract franchise), Bausch + Lomb and Glaukos on ophthalmic device demand, and RxSight on premium-lens elective spending. Because more than half of revenue clears through Chinese distributors, the name also carries a channel-inventory factor absent from most US-domiciled device peers: reported sales can lead or lag true implant volume by a quarter, which is what made both the 2025 crash and the 2026 recovery larger than end-demand justified. Ownership concentration — Broadwood at ~31%, Yunqi at 6.5%, institutions at 96.7% — means the effective float is small and moves are exaggerated in both directions on position changes.",
  "first_seen": "2026-04-22",
  "last_analyzed": "2026-07-19T11:44:04+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}